Independent
Tenure on this board
2.8 yrs
Also a director at
Natera Inc (NTRA)Arrivent Biopharma Inc (AVBP)Bioage Labs Inc (BIOA)Seaport Therapeutics Inc (SPTX)
3 nominees · 2 ballot items.
Election of three Class II directors (James Healy, M.D., Ph.D.; Robert J. Perez; Raymond Sanchez, M.D.) and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
Elect James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D. as Class II directors, each to serve a three-year term until the 2029 annual meeting and until their successors are duly elected and qualified.
Ratify the appointment of PricewaterhouseCoopers LLP as Rapport Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | TRV GP V, LLC | 14.92% | 7,135,233 | $223M |
| 2 | FMR LLC | 8.37% | 4,002,801 | $125M |
| 3 | ARCH Venture Management, LLC | 7.80% | 3,728,738 | $117M |
| 4 | FMR LLC | 6.62% | 3,166,138 | $99M |
| 5 | Capital International Investors | 6.48% | 3,097,973 | $97M |
| 6 | Cormorant Asset Management, LP | 6.18% | 2,957,521 | $93M |
| 7 | Sofinnova Investments, Inc. | 3.98% | 1,904,408 | $60M |
| 8 | JOHNSON JOHNSON | 3.73% | 1,784,517 | $56M |
| 9 | GOLDMAN SACHS GROUP INC | 3.51% | 1,680,576 | $53M |
| 10 | Polar Capital Holdings Plc | 3.43% | 1,642,461 | $51M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.